Symbiotec Pharmalab shares rose roughly 6% on Thursday, October 1, after investors reacted to a distribution‑rights announcement from its wholly‑owned subsidiary, Knovea Pharmaceutical. The filing, made after market hours on Wednesday, September 30, 2026, revealed that Knovea has secured exclusive rights to commercialise and distribute two Dual Chamber Vial (DCV) injectable products in the United States. The deal positions Symbiotec to tap a potential U.S. market of approximately $288 million, according to the company’s NSE disclosures.

On the day of the announcement, Symbiotec’s stock climbed to an intraday high of ₹1,246 per share, up from ₹1,176.75 at the previous close. By the afternoon, trading volumes across the NSE and BSE had surpassed 3.6 million equity shares, with the stock trading about 1% higher at ₹1,189.30. The 5.8% surge marked a significant move, reflecting investor confidence in the new U.S. partnership and the projected commercial potential of the DCV products.

Under the agreement, Knovea will lead development, regulatory submissions, manufacturing and supply of the DCV products, while Symbiotec’s partner will drive commercialisation and distribution across the United States. The collaboration is structured to deliver milestone payments tied to development, regulatory approval and commercial launch, with profit‑sharing commencing from the launch onwards. Anil Satwani, Managing Director of Symbiotec Pharmalab, highlighted that the company’s sustained investment in end‑to‑end DCV capabilities—from product development and regulatory science to commercial‑scale sterile manufacturing—is now yielding results through a partnership with a leading global pharmaceutical company.

Since its listing on the National Stock Exchange on September 1, 2026, Symbiotec Pharmalab shares have risen more than 26% from the IPO issue price of ₹988 per share. In the last month, the stock has gained over 10%, and in the last week it has climbed more than 18%. The company’s market capitalisation stood at ₹7,698 crore as of the October 1 session, reflecting the cumulative gains delivered to investors over the past months.

Anil Satwani, Managing Director of Symbiotec Pharmalab, said the company’s sustained investment in building DCV capabilities end‑to‑end—from product development and regulatory science to commercial‑scale sterile manufacturing—is now paying off, with a leading global pharmaceutical company as its exclusive U.S. partner. The announcement underscores Symbiotec’s strategy to expand its footprint in the lucrative U.S. injectable market, while the 5.8% share jump on October 1 highlights investor optimism about the partnership’s commercial prospects and the company’s growth trajectory.